Allakos Inc.

108.23+1.21+1.13%Vol 275.96K1Y Perf 31.30%
Sep 15th, 2021 16:00 DELAYED
BID108.22 ASK108.39
Open107.43 Previous Close107.02
Pre-Market- After-Market-
 - -%  - -
Target Price
181.33 
Analyst Rating
Moderate Buy 2.33
Potential %
67.54 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
39.75 
Earnings Rating
Buy
Market Cap5.84B 
Earnings Date
8th Nov 2021
Alpha0.04 Standard Deviation0.30
Beta0.89 

Today's Price Range

106.26109.25

52W Range

75.41157.98

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
7.16%
1 Month
35.30%
3 Months
21.25%
6 Months
-11.43%
1 Year
31.30%
3 Years
143.60%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALLK108.231.21001.13
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Earnings HistoryEstimateReportedSurprise %
Q02 2021-1.06-1.07-0.94
Q01 2021-0.78-1.04-33.33
Q04 2020-0.85-0.86-1.18
Q03 2020-0.83-0.86-3.61
Q02 2020-0.63-0.80-26.98
Q01 2020-0.62-0.578.06
Q04 2019-0.50-0.51-2.00
Q03 2019-0.45-0.47-4.44
Earnings Per EndEstimateRevision %Trend
9/2021 QR-1.130.88Positive
12/2021 QR-1.150.00-
12/2021 FY-4.450.22Positive
12/2022 FY-6.01-1.18Negative
Next Report Date8th Nov 2021
Estimated EPS Next Report-1.12
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume275.96K
Shares Outstanding54.00M
Shares Float25.12M
Trades Count5.49K
Dollar Volume34.38M
Avg. Volume254.36K
Avg. Weekly Volume260.53K
Avg. Monthly Volume220.71K
Avg. Quarterly Volume272.32K

Allakos Inc. (NASDAQ: ALLK) stock closed at 108.23 per share at the end of the most recent trading day (a 1.13% change compared to the prior day closing price) with a volume of 279.73K shares and market capitalization of 5.84B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Allakos Inc. CEO is Robert Alexander.

The one-year performance of Allakos Inc. stock is 31.3%, while year-to-date (YTD) performance is -22.69%. ALLK stock has a five-year performance of %. Its 52-week range is between 75.41 and 157.98, which gives ALLK stock a 52-week price range ratio of 39.75%

Allakos Inc. currently has a PE ratio of -27.50, a price-to-book (PB) ratio of 9.96, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.46%, a ROC of -37.22% and a ROE of -38.20%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Allakos Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.12 for the next earnings report. Allakos Inc.’s next earnings report date is 08th Nov 2021.

The consensus rating of Wall Street analysts for Allakos Inc. is Moderate Buy (2.33), with a target price of $181.33, which is +67.54% compared to the current price. The earnings rating for Allakos Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Allakos Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Allakos Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.29, ATR14 : 3.76, CCI20 : 124.96, Chaikin Money Flow : 0.38, MACD : 6.35, Money Flow Index : 100.00, ROC : 25.47, RSI : 82.56, STOCH (14,3) : 95.37, STOCH RSI : 1.00, UO : 65.57, Williams %R : -4.63), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Allakos Inc. in the last 12-months were: Adam Tomasi (Option Excercise at a value of $280 463), Adam Tomasi (Sold 349 507 shares of value $37 788 375 ), Daniel S. Janney (Sold 47 341 shares of value $5 669 135 ), Henrik S. Rasmussen (Option Excercise at a value of $127 875), Henrik S. Rasmussen (Sold 111 952 shares of value $12 905 844 ), John P. Mckearn (Sold 7 439 shares of value $855 485 ), Robert Alexander (Option Excercise at a value of $106 726), Robert Alexander (Sold 103 550 shares of value $11 682 246 ), Steven P. James (Option Excercise at a value of $1 838), Steven P. James (Sold 3 500 shares of value $425 775 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
2.33

Allakos Inc.

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

CEO: Robert Alexander

Telephone: +1 650 597-5002

Address: 975 Island Drive, Redwood City 94065, CA, US

Number of employees: 114

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

71%29%

Bearish Bullish

62%38%

Bearish Bullish

57%43%

News

Stocktwits